Suchergebnisse - "rucaparib"

PubPharm (112)

1

PARP inhibitor era in ovarian cancer treatment : a systematic review and meta-analysis of randomized controlled trials

enthalten in: Journal of ovarian research | 2024

von Baradács, I. | Teutsch, B. | Váradi, A. | +9

2

How far does a new horizon extend for rucaparib in metastatic prostate cancer?

enthalten in: Translational cancer research | 2024

von Karzai, F. | Madan, R. | Figg, W.

CommentOn: N Engl J Med. 2023 Feb 23;388(8):719-732. - PMID 36795891

3

Safety and efficacy of Rucaparib in the treatment of ovarian cancer and patients with BRCA mutation : a systematic review and meta-analysis of phase III randomized clinical trials

enthalten in: Expert review of anticancer therapy | 2024

von Mustafa, M. | Abushanab, A. | Mousa, M. | +4

4

The m6A regulator KIAA1429 stabilizes RAB27B mRNA and promotes the progression of chronic myeloid leukemia and resistance to targeted therapy

enthalten in: Genes & diseases | 2024

von Yao, F. | Zhong, F. | Jiang, J. | +10

5

Personalized medicine for metastatic prostate cancer : The paradigm of PARP inhibitors

enthalten in: Critical reviews in oncology/hematology | 2023

von Maiorano, B. | Conteduca, V. | Catalano, M. | +4

6

Poly (ADP-Ribose) Polymerase Inhibitors in Patients With Urothelial Cancer

enthalten in: Clinical genitourinary cancer | 2023

von Gamba, T. | Paparo, J. | Panepinto, O. | +3

7

Poly (ADP-ribose) Polymerase Inhibitors Have Comparable Efficacy with Platinum Chemotherapy in Patients with BRCA-positive Metastatic Castration-resistant Prostate Cancer. A Systematic Review and Meta-analysis

enthalten in: European urology oncology | 2023

von Fazekas, T. | Széles, �. | Teutsch, B. | +8

8

Efficacy and Safety of PARP Inhibitor Therapy in Advanced Ovarian Cancer : A Systematic Review and Network Meta-analysis of Randomized Controlled Trials

enthalten in: Current computer-aided drug design | 2023

von Chen, J. | Wu, X. | Wang, H. | +3

9

Patient-reported outcomes of maintenance rucaparib in patients with recurrent ovarian carcinoma in ARIEL3, a phase III, randomized, placebo-controlled trial

enthalten in: Gynecologic oncology | 2023

von Peipert, J. | Goble, S. | Isaacson, J. | +5

10

Rucaparib for PARP inhibitor-pretreated ovarian cancer : A GEICO retrospective subgroup analysis from the Spanish Rucaparib Access Program

enthalten in: Gynecologic oncology reports | 2023

von Yubero, A. | Estévez, P. | Barquín, A. | +8

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[12]